RestructuringJul 29, 2026, 04:09 PM
Adaptive Biotechnologies Plans Business Separation; Q2 Revenue $71.6M
AI Summary
Adaptive Biotechnologies reported Q2 2026 financial results, with total revenue increasing 22% to $71.6 million, driven by a 33% growth in its MRD business. The company announced plans to separate its MRD and Immune Medicine businesses to enhance long-term shareholder value. Additionally, Adaptive Biotechnologies completed a $345 million zero-coupon convertible senior notes offering, repaid the OrbiMed Purchase Agreement, and raised its full-year 2026 MRD revenue guidance to a new range of $268 million to $278 million. Despite an improved Adjusted EBITDA loss of $0.7 million, the company reported a net loss of $39.9 million for the quarter.
Key Highlights
- Adaptive Biotechnologies plans to separate its MRD and Immune Medicine businesses.
- Q2 2026 revenue increased 22% to $71.6 million.
- MRD business revenue grew 33% to $66.2 million.
- clonoSEQ test volume increased 43% to 36,111 tests.
- Completed a $345 million zero-coupon convertible senior notes offering.
- Raised full-year 2026 MRD revenue guidance to $268M-$278M.
- Net loss was $39.9 million, compared to $25.6 million in Q2 2025.
- Adjusted EBITDA loss improved to $0.7 million from $7.2 million.
Price Impact
More from ADPT